BioCentury
ARTICLE | Clinical News

Five Prime regains ground on cabiralizumab update

November 8, 2017 11:25 PM UTC

Five Prime Therapeutics Inc. (NASDAQ:FPRX) added $4.58 (18%) to $30.44 on Wednesday after reporting updated data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors and announcing upcoming trials sponsored by partner Bristol-Myers Squibb Co. (NYSE:BMY).

On Tuesday, Five Prime plummeted $17.90 (41%) to $25.86 following a preliminary readout from the Phase I trial reported in an abstract released ahead of the Society for Immunotherapy of Cancer meeting in National Harbor, Md. Among the abstract's 31 evaluable pancreatic cancer patients, cabiralizumab plus Opdivo led to an objective response rate (ORR) of 10%, including three confirmed partial responses in heavily pretreated patients without microsatellite instability (MSI) (see BioCentury Extra, Nov. 7)...